Emerging Therapy Solutions® (ETS) offers a comprehensive suite of services for solid organ and bone marrow transplant, cell and gene therapies, and other highly specialized therapies. These therapies can cost hundreds of thousands to millions of dollars per patient – and usually require unique reimbursement strategies and plans for catastrophic claims.
End to end, we are here to help you manage the immense costs, potential risks and intricate processes, especially as scientific breakthroughs rapidly bring more of these life-changing therapies to market.
Our leading services include:
When a member is referred for complex, high-cost care, we can help you evaluate and guide the terms and process.
We provide options and knowledge about where to receive care, and can compare available metrics to assist you in the decision-making process. To do this, we monitor and analyze comprehensive data, the clinical pipeline, existing reimbursement policies, compliance regulations and industry trends to fully understand the market.
Turn to us for:
We monitor the cell and gene preclinical and clinical trial landscape to identify conditions being targeted for genetic and cellular therapy. Our pipeline curation process spans from identification of conditions targeted by emerging cellular and gene therapies through pre-clinical, monitoring of the clinical trials, post-market approvals, the manufacturing market, and supply chain development. Our ETS medical services team of registered nurse clinical consultants offer content, consultation and a condition-specific knowledge base for these conditions and therapies in the pipeline.
We regularly convene expert clinical panels based on the emerging gene and cellular therapy pipeline that include leading medical researchers, clinical teams and facilities with experience and knowledge in each chosen therapeutic area.
We offer a full complement of materials and documents to help your team navigate this changing environment, with content available through subscription to our online ETS Knowledge Center Portal.
ETS has the tools, data, relationships, and expertise to quickly help you understand the risks related to approved and soon-to-be-approved high-cost and/or complex treatment options.
Our customized forecasts are purpose-built to estimate cost and utilization of emerging therapies specific to your population. Our models focus on the whole episode rather than the therapy alone to provide a clear picture of potential costs. Using these models, we can work with your strategy teams to advise on the expected range of outcomes to help with your cost containment and risk forecasting for these catastrophic claims.
To do this, we monitor the US clinical trial pipeline, analyze administrative claims data, model the unknowns, and leverage our relationships with independent physician experts to provide input to validate assumptions and develop algorithms.
As a result, your actuaries, finance team and underwriters can better understand the associated risk and anticipate your potential exposure, so your team can be prepared and keep pace.
Let ETS consulting services help you with plan design, analytics, clinical data modeling, policy design, and more related to high-cost and complex conditions. We specialize in these rare and high-cost conditions that many organizations do not have the scale to tackle. We offer a wealth of information, experience and content to design a solution specific to your needs.
You must be logged in to post a comment.